NCT06665074View on ClinicalTrials.gov

Inflammatory Challenge in Human Aggression.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

July 31, 2029

Study Completion Date

January 31, 2030

Conditions
Intermittent Explosive Disorder
Interventions
BIOLOGICAL

Endotoxin (E. coli O:113, Reference Endotoxin)

Dosage of endotoxin is 0.8 ng/Kg body Weight

OTHER

Saline (Placebo)

Volume of saline to be the same as volume of endotoxin

Trial Locations (1)

43210

The Ohio State University Medical Center, Columbus

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Ohio State University

OTHER